Single-center study of anti-angiogenic therapy with or without immune checkpoint inhibitors for previously treated small cell lung cancer

Small cell lung cancer (SCLC) has limited treatment options, especially after failure of initial therapy. A single-center cohort in China evaluated anti-angiogenic therapy with or without immune checkpoint inhibitors (ICIs) as second- or further line for SCLC. Combination therapy significantly improved progression-free survival (4.0 versus 2.7 months; p=0.029) and disease control rate (77.5% versus 52.4%; p=0.044) compared with anti-angiogenic monotherapy. Safety profiles were comparable between groups, with low rates of severe AEs. The authors conclude that anti-angiogenic therapy plus ICIs showed promising efficacy and safety for relapsed SCLC.